Saturday, June 6, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Empowering Physicians with Dr. Dana Corriel

Dana Corriel, MD, is a traditionally-trained physician who swapped clinical practice for digital entrepreneurship for innovation. After discovering she had a talent for design; unique content creating, during a short break from clinical medicine, she decided to “pay it forward” in her field of healthcare, and build an online platform that promoted doctors’ ideas; businesses. Corriel’s SoMeDocs was born. Today, she helps individuals AND companies alike to figure out next-steps in the online world. The ultimate mission of her company and work is to promote the autonomy of doctors everywhere, build a strong community of forward-thinking professionals, and provide well-needed networking in her field. To learn more about SoMeDocs, select the following link: doctorsonsocialmedia

#Corriel #SoMeDocs #physician #influencer #social #media

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Leave a Reply

Your email address will not be published. Required fields are marked *

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!